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Low-dose Erythropoietin reduces risk of heart failure induced 
by anti-cancer therapy
Melanie Hoch and Denise Hilfiker-Kleiner
Heart disease can be caused by many different 
insults and injuries and often terminates in death 
from heart failure, an inability of the heart muscle to 
adequately supply blood to the body. A major aim in 
today’s research is to define novel therapeutic strategies 
to limit myocardial damage and to enhance the ability 
of the heart muscle to regenerate and to heal itself.  The 
anti-cancer drug doxorubicin (DOX) is used to treat a 
broad range of cancers but is limited in its use by severe 
side effects, most notably heart failure [1]. STAT3 is an 
important factor that promotes survival and migration of 
many tumor cell types and its pharmacological blockade 
hold  good  promise  as  a  novel  anti-cancer  strategy  [2, 
3]. However, likewise to DOX, blocking STAT3 in the 
heart has been associated with heart failure in various 
experimental models [4, 5].  In our latest work, we found 
that low-doses of erythropoietin (EPO), a cytokine with 
multiple functions best known for its role to control the 
production of red blood cells, reduces the risk of heart 
failure mediated by DOX treatment or STAT3 blockade 
[6]. Our findings suggest that treatment with low-doses 
(hematocrit-inactive)  synthetic  EPO  (CERA)  during 
DOX treatment or STAT3 blockade is able to preserve the 
ability of cardiac progenitor cells to repair the vasculature 
of the heart and thereby to attenuate myocardial injury 
[6]. Recent studies have shown that the heart possesses 
intrinsic cardiac stem or progenitor cells that can contribute 
to  regeneration  and  healing  during  disease  and  aging 
[7]. Little is known about the molecules and pathways 
that regulate stem cell proliferation and differentiation. 
In  order  to  obtain  a  better  understanding  how  the 
cardiac  microenvironment  impacts  on  the  endogenous 
regeneration  system  of  the  adult  heart,  we  studied 
phenotypic alterations of resident cardiac progenitor cells 
(identified by the expression of Sca-1) in heart failure as 
a consequence of DOX treatment or genetic ablation of 
STAT3 in cardiac muscle cells. We observed that in both 
heart failure models, cardiac progenitor cells displayed 
an impaired ability to form new blood vessels essential 
for oxygen delivery to the heart muscle[6]. Both models 
also exhibited reduced production of EPO in the heart 
muscle[6]. Interestingly, we found that cardiac progenitor 
cells bind EPO within the cardiac microenvironment, a 
feature that seems to be required to maintain the ability 
to differentiate into new blood vessels[6]. Importantly, 
administration  of  the  synthetic  EPO  derivative  CERA 
at  a  low-dosage  (hematocrit-inactive)  restored  or 
preserved  the  endothelial  differentiation  potential  of 
cardiac  progenitor  cells  in  mice  with  depleted  STAT3 
or in mice obtaining DOX treatment. Moreover, CERA 
preserved heart blood vessels and cardiac function in both 
mouse models[6]. Our data imply that short-term EPO 
administration at low-doses seems an attractive avenue 
to pursue for protecting the heart against chemotherapy-
induced failure and might even have broader applications 
in cardiac regeneration[6]. However, further evaluation of 
EPO in tumor research is required, especially with regard 
to its effect on tumor growth and anti-tumor treatment 
strategies.
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